Join our daily newsletter At The Bell to receive exclusive market insights
- Chimeric Therapeutics (CHM) releases two CLTX CAR T abstracts showing positive results from its phase one clinical trial
- The clinical data comes from an ongoing phase one study of four patients with recurrent or progressive glioblastoma
- Following treatment, the patients showed a disease control rate of 75 per cent, with three out of the four patients returning a best response of stable disease and no dose limiting toxicity
- The CLTX CAR T phase one clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022
- Chimeric Therapeutics last traded at 32 cents per share on November 12
Chimeric Therapeutics (CHM) has released two CLTX CAR T abstracts which show positive results from its phase one clinical trial.
The two abstracts will be presented at the Society for Neuro-Oncology 27th annual scientific meeting on November 19.
The first abstract, ‘Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma’, provided insight into the initial clinical data for CLTX.
The second, ‘Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognise glioblastoma cells?’ expanded on the translational understanding of Chlorotoxin (CLTX) activity.
The clinical data released in the first abstract was from an ongoing CLTX CAR T phase one clinical trial in patients with recurrent or progressive glioblastoma. The data focused on four patients who were each treated with Chimeric’s formulation.
Following treatment, the patients showed a disease control rate of 75 per cent, with three out of the four patients returning a best response of stable disease. The CLTX CAR T cells were generally well tolerated and none of the patients experienced a dose limiting toxicity.
Chimeric’s CEO and Managing Director Jennifer Chow said the initial data was highly encouraging as it demonstrated that CLTX CAR T cells were eliciting disease control in recurrent glioblastoma even at the lowest, sub-therapeutic dose level.
“Achieving disease control in three of the four patients treated at this first dose level, along with the generally well tolerated safety profile that was demonstrated, provides us with great enthusiasm for progressing the trial through the higher dose levels and dual routes of administration,” Ms Chow said.
The CLTX CAR T phase 1 clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022.
Chimeric Therapeutics last traded at 32 cents per share on November 12.
